Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Acadia initiates second Phase III Parkinson’s disease trial
The trial is designed to evaluate the safety and efficacy of pimavanserin in approximately 240 patients with Parkinson’s disease psychosis (PDP). Patients in the trial will be randomized
The trial is designed to evaluate the safety and efficacy of pimavanserin in approximately 240 patients with Parkinson’s disease psychosis (PDP). Patients in the trial will be randomized
Under the terms of the agreement, InSite grants exclusive rights to Bioceutica to commercialize AzaSite for ocular bacterial infection in Argentina, Chile, Paraguay and Uruguay. Bioceutica will also
The Care II trial began in February at St Vincent’s Hospital in Melbourne, Australia, and, so far, has led to successful implantations in 12 patients. The multi-site Care
The preclinical results also showed that ranolazine increased glucose-stimulated insulin secretion (GSIS) in a dose-dependent manner in isolated islets. Acute administration of ranolazine to animals also significantly increased
Gen-Probe expects to enroll approximately 7,000 women in the study. Actual enrollment, however, may vary based on the prevalence of cervical disease among women in the trial. The
Gross proceeds to the company are expected to be approximately $5.3 million. In the purchase agreement, Nordic Biotech Opportunity Fund, an affiliate of Nordic Biotech, the company’s largest
Under the agreement, in exchange for exclusive worldwide commercial rights to Gvax, Takeda will pay Cell Genesys an upfront payment of $50 million and additional milestone payments totaling
The study is designed to evaluate the anti-tumor effect and safety/tolerability of liposomal paclitaxel (LEP-ETU). The study will target enrolling 35 patients in five centers with histologically or
In 2005, Scynexis was selected as the primary research partner for Merial, an animal health company, in an agreement that included up to $150 million in research funding
According to data collected by Thomson, the Toronto-based financial-information provider, the companies raised their US wholesale prices by 9% on their 10 top-selling medicines in 2007, more than